

Preliminary Amendment -1-
showing changes for
§ 371 Patent Application of PCT/EP00/02410
Markl, et al.
filed September 17, 2001

1. Nucleic acid molecule comprising a nucleic acid sequence which codes for a haemocyanin, a haemocyanin domain or a functional fragment thereof with the immunological properties of at least one domain of a haemocyanin, the nucleic acid sequence being selected from:

(b) nucleic acid sequences which are selected from the group consisting of the DNA sequences shown below or the corresponding RNA sequences or which contain these:

SEQ ID NO:1 (HtH1 domain a + signal peptide),
SEQ ID NO:2 (HtH1 domain b),
SEQ ID NO:3 (HtH1 domain c),
SEQ ID NO:4 (HtH1 domain d),
SEQ ID NO:5 (HtH1 domain e),
SEQ ID NO:6 (HtH1 domain f),
SEQ ID NO:7 (HtH1 domain g),
SEQ ID NO: 8 (HtH1 domain h),
SEQ ID NO:9 (partial HtH2 domain b),
SEQ ID NO:10 (HtH2 domain c),
SEQ ID NO:11 (HtH2 domain d),
SEQ ID NO:12 (HtH2 domain e),
SEQ ID NO:13 (HtH2 domain f),
SEQ ID NO:14 (HtH2 domain g),
SEQ ID NO:15 (HtH2 domain h),
SEQ ID NO:16 (partial KLH1 domain b),
SEQ ID NO:17 (KLH1 domain c),
SEQ ID NO:18 (KLH1 domain d),

Preliminary Amendment -2-
showing changes for
§ 371 Patent Application of PCT/EP00/02410
Markl, et al.
filed September 17, 2001

SEQ ID NO:19 (partial KLH1 domain e),
SEQ ID NO:20 (KLH2 domain b),
SEQ ID NO:21 (KLH2 domain c),
SEQ ID NO:22 (partial KLH2 domain d),
SEQ ID NO:23 (KLH2 domain g),
SEQ ID NO:24 (partial KLH2 domain h),
SEQ ID NO:49 (HtH1 domain a' + signal peptide),
SEQ ID NO:50 (partial HtH2 domain a),
SEQ ID NO:51 (HtH2 domain b'),
SEQ ID NO:52 (HtH2 domain d'),
SEQ ID NO:53 (HtH2 domain e'),
SEQ ID NO:54 (KLH1 domain e'),
SEQ ID NO:55 (KLH1 domain f),
SEQ ID NO:56 (KLH1 domain g),
SEQ ID NO:57 (KLH2 domain b'),
SEQ ID NO:58 (KLH2 domain c'),
SEQ ID NO:59 (KLH2 domain d'),
SEQ ID NO:60 (KLH2 domain e),
SEQ ID NO:61 (KLH2 domain f),
SEQ ID NO:62 (KLH2 domain g'),
SEQ ID NO:80 (HtH1 domain a" + signal peptide),
SEQ ID NO:81 (HtH1 domain b"),
SEQ ID NO:82 (HtH1 domain c"),
SEQ ID NO:83 (HtH1 domain d"),
SEQ ID NO:84 (HtH1 domain e"),
SEQ ID NO:85 (HtH1 domain f"),
SEQ ID NO:86 (HtH1 domain g"),
SEQ ID NO:87 (HtH1 domain h"),
SEQ ID NO:88 (partial HtH2 domain a"),
SEQ ID NO:89 (HtH2 domain b"),
SEQ ID NO:90 (HtH2 domain c"),

Preliminary Amendment -3-
showing changes for
§ 371 Patent Application of PCT/EP00/02410
Markl, et al.
filed September 17, 2001

SEQ ID NO:91 (HtH2 domain d"),
SEQ ID NO:92 (HtH2 domain e"),
SEQ ID NO:93 (HtH2 domain f"),
SEQ ID NO:94 (HtH2 domain g"),
SEQ ID NO:95 (HtH2 domain h"),
SEQ ID NO:96 (partial KLH1 domain b"),
SEQ ID NO:97 (KLH1 domain c"),
SEQ ID NO:98 (KLH1 domain d"),
SEQ ID NO:99 (KLH1 domain e"),
SEQ ID NO:100 (KLH1 domain f"),
SEQ ID NO:101 (KLH1 domain g"),
SEQ ID NO:102 (KLH2 domain b"),
SEQ ID NO:103 (KLH2 domain c"),
SEQ ID NO:104 (KLH2 domain d"),
SEQ ID NO:105 (KLH2 domain e"),
SEQ ID NO:106 (KLH2 domain f"),
SEQ ID NO:107 (KLH2 domain g"),
SEQ ID NO:108 (partial KLH2 domain h");

- (b) nucleic acid sequences which hybridize with the counter-strand of a nucleic acid sequence according to (a) and code for a polypeptide which has the immunological properties of at least one domain of a haemocyanin;
- (c) nucleic acid sequences which on the basis of the genetic code are degenerated to the DNA sequences defined under (a) and (b) and code for a polypeptide which has the immunological properties of at least one domain of a haemocyanin;
- (d) nucleic acid sequences which hybridize with one

Preliminary Amendment -4-
showing changes for
§ 371 Patent Application of PCT/EP00/02410
Markl, et al.
filed September 17, 2001

of the nucleic acid sequences described under (a) to (c) and the counter-strand of which codes for a polypeptide which has the immunological properties of at least one domain of a haemocyanin;

- (e) nucleic acid sequences which are at least 60% homologous to one of the nucleic acid sequences described under (a);
- (f) variants of the sequences described under (a) to (d), the variants containing additions, deletions, insertions or inversions with respect to the sequences described under (a) to (d) and coding for a polypeptide which has the immunological properties of at least one domain of haemocyanin; and
- (g) combinations of several of the DNA sequences described under (a) to (f).

2. Nucleic acid molecule according to claim 1, **characterized in that** the hybridization described under (b) or (d) is carried out under stringent conditions.

3. Nucleic acid molecule according to claim 1, **characterized in that** the nucleic acid molecule described under (e) is at least 80% homologous to one of the nucleic acid sequences described under (a).

4. Nucleic acid molecule according to claim 1,

Preliminary Amendment -5-
showing changes for
§ 371 Patent Application of PCT/EP00/02410
Markl, et al.
filed September 17, 2001

characterized in that the nucleic acid molecule described under (e) is at least 90 % homologous to one of the nucleic acid sequences described under (a).

5. Nucleic acid molecule according to claim 1, **characterized in that** the nucleic acid molecule described under (e) is at least 95 % homologous to one of the nucleic acid sequences described under (a).

6. Nucleic acid molecule according to ~~one of claims 1 to 5~~, **characterized in that** it is a deoxyribonucleic acid molecule.

7. Construct comprising a nucleic acid molecule comprising a nucleic acid sequence which codes for a haemocyanin, a haemocyanin domain or a functional fragment thereof with the immunological properties of at least one domain of a haemocyanin, the nucleic acid sequence being selected from:

(b) nucleic acid sequences which are selected from the group consisting of the DNA sequences shown below or the corresponding RNA sequences or which contain these:

SEQ ID NO:1 (HtH1 domain a + signal peptide),
SEQ ID NO:2 (HtH1 domain b),
SEQ ID NO:3 (HtH1 domain c),
SEQ ID NO:4 (HtH1 domain d),

Preliminary Amendment -6-
showing changes for
§ 371 Patent Application of PCT/EP00/02410
Markl, et al.
filed September 17, 2001

SEQ ID NO:5 (HtH1 domain e),
SEQ ID NO:6 (HtH1 domain f),
SEQ ID NO:7 (HtH1 domain g),
SEQ ID NO: 8 (HtH1 domain h),
SEQ ID NO:9 (partial HtH2 domain b),
SEQ ID NO:10 (HtH2 domain c),
SEQ ID NO:11 (HtH2 domain d),
SEQ ID NO:12 (HtH2 domain e),
SEQ ID NO:13 (HtH2 domain f),
SEQ ID NO:14 (HtH2 domain g),
SEQ ID NO:15 (HtH2 domain h),
SEQ ID NO:16 (partial KLH1 domain b),
SEQ ID NO:17 (KLH1 domain c),
SEQ ID NO:18 (KLH1 domain d),
SEQ ID NO:19 (partial KLH1 domain e),
SEQ ID NO:20 (KLH2 domain b),
SEQ ID NO:21 (KLH2 domain c),
SEQ ID NO:22 (partial KLH2 domain d),
SEQ ID NO:23 (KLH2 domain g),
SEQ ID NO:24 (partial KLH2 domain h),
SEQ ID NO:49 (HtH1 domain a' + signal peptide),
SEQ ID NO:50 (partial HtH2 domain a),
SEQ ID NO:51 (HtH2 domain b'),
SEQ ID NO:52 (HtH2 domain d'),
SEQ ID NO:53 (HtH2 domain e'),
SEQ ID NO:54 (KLH1 domain e'),
SEQ ID NO:55 (KLH1 domain f),
SEQ ID NO:56 (KLH1 domain g),
SEQ ID NO:57 (KLH2 domain b'),
SEQ ID NO:58 (KLH2 domain c'),
SEQ ID NO:59 (KLH2 domain d'),

Preliminary Amendment -7-
showing changes for
§ 371 Patent Application of PCT/EP00/02410
Markl, et al.
filed September 17, 2001

SEQ ID NO:60 (KLH2 domain e),
SEQ ID NO:61 (KLH2 domain f),
SEQ ID NO:62 (KLH2 domain g'),
SEQ ID NO:80 (HtH1 domain a" + signal peptide),
SEQ ID NO:81 (HtH1 domain b"),
SEQ ID NO:82 (HtH1 domain c"),
SEQ ID NO:83 (HtH1 domain d"),
SEQ ID NO:84 (HtH1 domain e"),
SEQ ID NO:85 (HtH1 domain f"),
SEQ ID NO:86 (HtH1 domain g"),
SEQ ID NO:87 (HtH1 domain h"),
SEQ ID NO:88 (partial HtH2 domain a"),
SEQ ID NO:89 (HtH2 domain b"),
SEQ ID NO:90 (HtH2 domain c"),
SEQ ID NO:91 (HtH2 domain d"),
SEQ ID NO:92 (HtH2 domain e"),
SEQ ID NO:93 (HtH2 domain f"),
SEQ ID NO:94 (HtH2 domain g"),
SEQ ID NO:95 (HtH2 domain h"),
SEQ ID NO:96 (partial KLH1 domain b"),
SEQ ID NO:97 (KLH1 domain c"),
SEQ ID NO:98 (KLH1 domain d"),
SEQ ID NO:99 (KLH1 domain e"),
SEQ ID NO:100 (KLH1 domain f"),
SEQ ID NO:101 (KLH1 domain g"),
SEQ ID NO:102 (KLH2 domain b"),
SEQ ID NO:103 (KLH2 domain c"),
SEQ ID NO:104 (KLH2 domain d"),
SEQ ID NO:105 (KLH2 domain e"),
SEQ ID NO:106 (KLH2 domain f"),
SEQ ID NO:107 (KLH2 domain g"),

Preliminary Amendment -8-
showing changes for
§ 371 Patent Application of PCT/EP00/02410
Markl, et al.
filed September 17, 2001

SEQ ID NO:108 (partial KLH2 domain h");

- (b) nucleic acid sequences which hybridize with the counter-strand of a nucleic acid sequence according to (a) and code for a polypeptide which has the immunological properties of at least one domain of a haemocyanin;
- (c) nucleic acid sequences which on the basis of the genetic code are degenerated to the DNA sequences defined under (a) and (b) and code for a polypeptide which has the immunological properties of at least one domain of a haemocyanin;
- (d) nucleic acid sequences which hybridize with one of the nucleic acid sequences described under (a) to (c) and the counter-strand of which codes for a polypeptide which has the immunological properties of at least one domain of a haemocyanin;
- (e) nucleic acid sequences which are at least 60% homologous to one of the nucleic acid sequences described under (a);
- (f) variants of the sequences described under (a) to (d), the variants containing additions, deletions, insertions or inversions with respect to the sequences described under (a) to (d) and coding for a polypeptide which has the immunological properties of at least one domain of haemocyanin;
and

Preliminary Amendment -9-
showing changes for
§ 371 Patent Application of PCT/EP00/02410
Markl, et al.
filed September 17, 2001

(g) combinations of several of the DNA sequences
described under (a) to (f)
~~according to one of claims 1 to 6.~~

8. Construct according to claim 7, furthermore comprising a promoter which is suitable for expression control, the nucleic acid sequence which codes for a haemocyanin, a haemocyanin domain or a functional fragment thereof being under the control of the promoter.

9. Construct according to claim 7-~~or 8~~, furthermore comprising a nucleic acid sequence which codes for an antigen and is coupled directly to the nucleic acid sequence which codes for a haemocyanin, a haemocyanin domain or a functional fragment thereof.

10. Construct according to claim 9, wherein the antigen is selected from: _tumour antigens, virus antigens and antigens of bacterial or parasitic pathogens.

11. Construct according to ~~one of claims 7 to 10~~, wherein the construct comprises at least a part of a vector, the vector being selected from:
bacteriophages, adenoviruses, vaccinia viruses, baculoviruses, SV40 virus and retroviruses.

12. Construct according to ~~one of claims 7 to 11~~, wherein the construct furthermore comprises a His tag-coding nucleic acid sequence and the expression

Preliminary Amendment -10-
showing changes for
§ 371 Patent Application of PCT/EP00/02410
Markl, et al.
filed September 17, 2001

of the construct leads to the formation of a fusion
protein with a His tag.

13. Host cell containing a construct ~~according to~~
~~one of claims 7 to 12~~, wherein the host cell is a
prokaryotic or eukaryotic cell suitable for
expression of the construct and wherein said
construct comprises a nucleic acid molecule
comprising a nucleic acid sequence which codes for a
haemocyanin, a haemocyanin domain or a functional
fragment thereof with the immunological properties of
at least one domain of a haemocyanin, the nucleic
acid sequence being selected from:

(b) nucleic acid sequences which are selected from
the group consisting of the DNA sequences shown
below or the corresponding RNA sequences or which
contain these:

SEQ ID NO:1 (HtH1 domain a + signal peptide),
SEQ ID NO:2 (HtH1 domain b),
SEQ ID NO:3 (HtH1 domain c),
SEQ ID NO:4 (HtH1 domain d),
SEQ ID NO:5 (HtH1 domain e),
SEQ ID NO:6 (HtH1 domain f),
SEQ ID NO:7 (HtH1 domain g),
SEQ ID NO: 8 (HtH1 domain h),
SEQ ID NO:9 (partial HtH2 domain b),
SEQ ID NO:10 (HtH2 domain c),
SEQ ID NO:11 (HtH2 domain d),
SEQ ID NO:12 (HtH2 domain e),

Preliminary Amendment -11-
showing changes for
§ 371 Patent Application of PCT/EP00/02410
Markl, et al.
filed September 17, 2001

SEQ ID NO:13 (HtH2 domain f),
SEQ ID NO:14 (HtH2 domain g),
SEQ ID NO:15 (HtH2 domain h),
SEQ ID NO:16 (partial KLH1 domain b),
SEQ ID NO:17 (KLH1 domain c),
SEQ ID NO:18 (KLH1 domain d),
SEQ ID NO:19 (partial KLH1 domain e),
SEQ ID NO:20 (KLH2 domain b),
SEQ ID NO:21 (KLH2 domain c),
SEQ ID NO:22 (partial KLH2 domain d),
SEQ ID NO:23 (KLH2 domain g),
SEQ ID NO:24 (partial KLH2 domain h),
SEQ ID NO:49 (HtH1 domain a' + signal peptide),
SEQ ID NO:50 (partial HtH2 domain a),
SEQ ID NO:51 (HtH2 domain b'),
SEQ ID NO:52 (HtH2 domain d'),
SEQ ID NO:53 (HtH2 domain e'),
SEQ ID NO:54 (KLH1 domain e'),
SEQ ID NO:55 (KLH1 domain f),
SEQ ID NO:56 (KLH1 domain g),
SEQ ID NO:57 (KLH2 domain b'),
SEQ ID NO:58 (KLH2 domain c'),
SEQ ID NO:59 (KLH2 domain d'),
SEQ ID NO:60 (KLH2 domain e),
SEQ ID NO:61 (KLH2 domain f),
SEQ ID NO:62 (KLH2 domain g'),
SEQ ID NO:80 (HtH1 domain a" + signal peptide),
SEQ ID NO:81 (HtH1 domain b"),
SEQ ID NO:82 (HtH1 domain c"),
SEQ ID NO:83 (HtH1 domain d"),
SEQ ID NO:84 (HtH1 domain e"),

Preliminary Amendment -12-
showing changes for
§ 371 Patent Application of PCT/EP00/02410
Markl, et al.
filed September 17, 2001

SEQ ID NO:85 (HtH1 domain f"),
SEQ ID NO:86 (HtH1 domain g"),
SEQ ID NO:87 (HtH1 domain h"),
SEQ ID NO:88 (partial HtH2 domain a"),
SEQ ID NO:89 (HtH2 domain b"),
SEQ ID NO:90 (HtH2 domain c"),
SEQ ID NO:91 (HtH2 domain d"),
SEQ ID NO:92 (HtH2 domain e"),
SEQ ID NO:93 (HtH2 domain f"),
SEQ ID NO:94 (HtH2 domain g"),
SEQ ID NO:95 (HtH2 domain h"),
SEQ ID NO:96 (partial KLH1 domain b"),
SEQ ID NO:97 (KLH1 domain c"),
SEQ ID NO:98 (KLH1 domain d"),
SEQ ID NO:99 (KLH1 domain e"),
SEQ ID NO:100 (KLH1 domain f"),
SEQ ID NO:101 (KLH1 domain g"),
SEQ ID NO:102 (KLH2 domain b"),
SEQ ID NO:103 (KLH2 domain c"),
SEQ ID NO:104 (KLH2 domain d"),
SEQ ID NO:105 (KLH2 domain e"),
SEQ ID NO:106 (KLH2 domain f"),
SEQ ID NO:107 (KLH2 domain g"),
SEQ ID NO:108 (partial KLH2 domain h");

(b) nucleic acid sequences which hybridize with the
counter-strand of a nucleic acid sequence
according to (a) and code for a polypeptide which
has the immunological properties of at least one
domain of a haemocyanin;

Preliminary Amendment -13-
showing changes for
§ 371 Patent Application of PCT/EP00/02410
Markl, et al.
filed September 17, 2001

- (c) nucleic acid sequences which on the basis of the genetic code are degenerated to the DNA sequences defined under (a) and (b) and code for a polypeptide which has the immunological properties of at least one domain of a haemocyanin;
- (d) nucleic acid sequences which hybridize with one of the nucleic acid sequences described under (a) to (c) and the counter-strand of which codes for a polypeptide which has the immunological properties of at least one domain of a haemocyanin;
- (e) nucleic acid sequences which are at least 60% homologous to one of the nucleic acid sequences described under (a);
- (f) variants of the sequences described under (a) to (d), the variants containing additions, deletions, insertions or inversions with respect to the sequences described under (a) to (d) and coding for a polypeptide which has the immunological properties of at least one domain of haemocyanin; and
- (g) combinations of several of the DNA sequences described under (a) to (f).

14. Host cell according to claim 13, **characterized in that** the prokaryotic host cell is selected from E. coli and Bacillus subtilis.

Preliminary Amendment -14-
showing changes for
§ 371 Patent Application of PCT/EP00/02410
Markl, et al.
filed September 17, 2001

15. Host cell according to claim 13, **characterized in that** the eukaryotic host cell is selected from yeast cells, plant cells, insect cells and mammalian cells, preferably from CHO cells, COS cells and HeLa cells.

16. Process for the preparation of a haemocyanin polypeptide, wherein ~~the~~ nucleic acid molecule ~~according to one of claims 1 to 6 and/or the~~ construct comprising said nucleic acid molecule~~according to one of claims 7 to 12~~ is expressed in a suitable host cell and the protein is isolated, if appropriate, wherein said nucleic acid molecule comprising a nucleic acid molecule comprises a nucleic acid sequence which codes for a haemocyanin, a haemocyanin domain or a functional fragment thereof with the immunological properties of at least one domain of a haemocyanin, the nucleic acid sequence being selected from:

(b) nucleic acid sequences which are selected from the group consisting of the DNA sequences shown below or the corresponding RNA sequences or which contain these:

SEQ ID NO:1 (HtH1 domain a + signal peptide),
SEQ ID NO:2 (HtH1 domain b),
SEQ ID NO:3 (HtH1 domain c),
SEQ ID NO:4 (HtH1 domain d),
SEQ ID NO:5 (HtH1 domain e),
SEQ ID NO:6 (HtH1 domain f),

Preliminary Amendment -15-
showing changes for
§ 371 Patent Application of PCT/EP00/02410
Markl, et al.
filed September 17, 2001

SEQ ID NO:7 (HtH1 domain g),
SEQ ID NO: 8 (HtH1 domain h),
SEQ ID NO:9 (partial HtH2 domain b),
SEQ ID NO:10 (HtH2 domain c),
SEQ ID NO:11 (HtH2 domain d),
SEQ ID NO:12 (HtH2 domain e),
SEQ ID NO:13 (HtH2 domain f),
SEQ ID NO:14 (HtH2 domain g),
SEQ ID NO:15 (HtH2 domain h),
SEQ ID NO:16 (partial KLH1 domain b),
SEQ ID NO:17 (KLH1 domain c),
SEQ ID NO:18 (KLH1 domain d),
SEQ ID NO:19 (partial KLH1 domain e),
SEQ ID NO:20 (KLH2 domain b),
SEQ ID NO:21 (KLH2 domain c),
SEQ ID NO:22 (partial KLH2 domain d),
SEQ ID NO:23 (KLH2 domain g),
SEQ ID NO:24 (partial KLH2 domain h),
SEQ ID NO:49 (HtH1 domain a' + signal peptide),
SEQ ID NO:50 (partial HtH2 domain a),
SEQ ID NO:51 (HtH2 domain b'),
SEQ ID NO:52 (HtH2 domain d'),
SEQ ID NO:53 (HtH2 domain e'),
SEQ ID NO:54 (KLH1 domain e'),
SEQ ID NO:55 (KLH1 domain f),
SEQ ID NO:56 (KLH1 domain g),
SEQ ID NO:57 (KLH2 domain b'),
SEQ ID NO:58 (KLH2 domain c'),
SEQ ID NO:59 (KLH2 domain d'),
SEQ ID NO:60 (KLH2 domain e),
SEQ ID NO:61 (KLH2 domain f),

Preliminary Amendment -16-
showing changes for
§ 371 Patent Application of PCT/EP00/02410
Markl, et al.
filed September 17, 2001

SEQ ID NO:62 (KLH2 domain g'),
SEQ ID NO:80 (HtH1 domain a" + signal peptide),
SEQ ID NO:81 (HtH1 domain b"),
SEQ ID NO:82 (HtH1 domain c"),
SEQ ID NO:83 (HtH1 domain d"),
SEQ ID NO:84 (HtH1 domain e"),
SEQ ID NO:85 (HtH1 domain f"),
SEQ ID NO:86 (HtH1 domain g"),
SEQ ID NO:87 (HtH1 domain h"),
SEQ ID NO:88 (partial HtH2 domain a"),
SEQ ID NO:89 (HtH2 domain b"),
SEQ ID NO:90 (HtH2 domain c"),
SEQ ID NO:91 (HtH2 domain d"),
SEQ ID NO:92 (HtH2 domain e"),
SEQ ID NO:93 (HtH2 domain f"),
SEQ ID NO:94 (HtH2 domain g"),
SEQ ID NO:95 (HtH2 domain h"),
SEQ ID NO:96 (partial KLH1 domain b"),
SEQ ID NO:97 (KLH1 domain c"),
SEQ ID NO:98 (KLH1 domain d"),
SEQ ID NO:99 (KLH1 domain e"),
SEQ ID NO:100 (KLH1 domain f"),
SEQ ID NO:101 (KLH1 domain g"),
SEQ ID NO:102 (KLH2 domain b"),
SEQ ID NO:103 (KLH2 domain c"),
SEQ ID NO:104 (KLH2 domain d"),
SEQ ID NO:105 (KLH2 domain e"),
SEQ ID NO:106 (KLH2 domain f"),
SEQ ID NO:107 (KLH2 domain g"),
SEQ ID NO:108 (partial KLH2 domain h");

Preliminary Amendment -17-
showing changes for
§ 371 Patent Application of PCT/EP00/02410
Markl, et al.
filed September 17, 2001

- (b) nucleic acid sequences which hybridize with the counter-strand of a nucleic acid sequence according to (a) and code for a polypeptide which has the immunological properties of at least one domain of a haemocyanin;
- (c) nucleic acid sequences which on the basis of the genetic code are degenerated to the DNA sequences defined under (a) and (b) and code for a polypeptide which has the immunological properties of at least one domain of a haemocyanin;
- (d) nucleic acid sequences which hybridize with one of the nucleic acid sequences described under (a) to (c) and the counter-strand of which codes for a polypeptide which has the immunological properties of at least one domain of a haemocyanin;
- (e) nucleic acid sequences which are at least 60% homologous to one of the nucleic acid sequences described under (a);
- (f) variants of the sequences described under (a) to (d), the variants containing additions, deletions, insertions or inversions with respect to the sequences described under (a) to (d) and coding for a polypeptide which has the immunological properties of at least one domain of haemocyanin; and
- (g) combinations of several of the DNA sequences described under (a) to (f).

Preliminary Amendment -18-
showing changes for
§ 371 Patent Application of PCT/EP00/02410
Markl, et al.
filed September 17, 2001

17. Process according to claim 16, **characterized in that** the haemocyanin polypeptide prepared is modified naturally or chemically.

18. Process according to claim 17, **characterized in that** the modification is a crosslinking or a covalent bonding to an antigen.

19. Process according to ~~one of~~ claims 16 to 18, **characterized in that** the expression is carried out in a host cell ~~according to one of claims 13 to 15.~~

20. Haemocyanin polypeptide, comprising an amino acid sequence which is coded by one or more of athe nucleic acid molecules comprising a nucleic acid sequence which codes for a haemocyanin, a haemocyanin domain or a functional fragment thereof with the immunological properties of at least one domain of a haemocyanin, the nucleic acid sequence being selected from:

(b) nucleic acid sequences which are selected from the group consisting of the DNA sequences shown below or the corresponding RNA sequences or which contain these:

SEQ ID NO:1 (HtH1 domain a + signal peptide),
SEQ ID NO:2 (HtH1 domain b),
SEQ ID NO:3 (HtH1 domain c),
SEQ ID NO:4 (HtH1 domain d),

Preliminary Amendment -19-
showing changes for
§ 371 Patent Application of PCT/EP00/02410
Markl, et al.
filed September 17, 2001

SEQ ID NO:5 (HtH1 domain e),
SEQ ID NO:6 (HtH1 domain f),
SEQ ID NO:7 (HtH1 domain g),
SEQ ID NO: 8 (HtH1 domain h),
SEQ ID NO:9 (partial HtH2 domain b),
SEQ ID NO:10 (HtH2 domain c),
SEQ ID NO:11 (HtH2 domain d),
SEQ ID NO:12 (HtH2 domain e),
SEQ ID NO:13 (HtH2 domain f),
SEQ ID NO:14 (HtH2 domain g),
SEQ ID NO:15 (HtH2 domain h),
SEQ ID NO:16 (partial KLH1 domain b),
SEQ ID NO:17 (KLH1 domain c),
SEQ ID NO:18 (KLH1 domain d),
SEQ ID NO:19 (partial KLH1 domain e),
SEQ ID NO:20 (KLH2 domain b),
SEQ ID NO:21 (KLH2 domain c),
SEQ ID NO:22 (partial KLH2 domain d),
SEQ ID NO:23 (KLH2 domain g),
SEQ ID NO:24 (partial KLH2 domain h),
SEQ ID NO:49 (HtH1 domain a' + signal peptide),
SEQ ID NO:50 (partial HtH2 domain a),
SEQ ID NO:51 (HtH2 domain b'),
SEQ ID NO:52 (HtH2 domain d'),
SEQ ID NO:53 (HtH2 domain e'),
SEQ ID NO:54 (KLH1 domain e'),
SEQ ID NO:55 (KLH1 domain f),
SEQ ID NO:56 (KLH1 domain g),
SEQ ID NO:57 (KLH2 domain b'),
SEQ ID NO:58 (KLH2 domain c'),
SEQ ID NO:59 (KLH2 domain d'),

Preliminary Amendment -20-
showing changes for
§ 371 Patent Application of PCT/EP00/02410
Markl, et al.
filed September 17, 2001

SEQ ID NO:60 (KLH2 domain e),
SEQ ID NO:61 (KLH2 domain f),
SEQ ID NO:62 (KLH2 domain g'),
SEQ ID NO:80 (HtH1 domain a" + signal peptide),
SEQ ID NO:81 (HtH1 domain b"),
SEQ ID NO:82 (HtH1 domain c"),
SEQ ID NO:83 (HtH1 domain d"),
SEQ ID NO:84 (HtH1 domain e"),
SEQ ID NO:85 (HtH1 domain f"),
SEQ ID NO:86 (HtH1 domain g"),
SEQ ID NO:87 (HtH1 domain h"),
SEQ ID NO:88 (partial HtH2 domain a"),
SEQ ID NO:89 (HtH2 domain b"),
SEQ ID NO:90 (HtH2 domain c"),
SEQ ID NO:91 (HtH2 domain d"),
SEQ ID NO:92 (HtH2 domain e"),
SEQ ID NO:93 (HtH2 domain f"),
SEQ ID NO:94 (HtH2 domain g"),
SEQ ID NO:95 (HtH2 domain h"),
SEQ ID NO:96 (partial KLH1 domain b"),
SEQ ID NO:97 (KLH1 domain c"),
SEQ ID NO:98 (KLH1 domain d"),
SEQ ID NO:99 (KLH1 domain e"),
SEQ ID NO:100 (KLH1 domain f"),
SEQ ID NO:101 (KLH1 domain g"),
SEQ ID NO:102 (KLH2 domain b"),
SEQ ID NO:103 (KLH2 domain c"),
SEQ ID NO:104 (KLH2 domain d"),
SEQ ID NO:105 (KLH2 domain e"),
SEQ ID NO:106 (KLH2 domain f"),
SEQ ID NO:107 (KLH2 domain g"),

Preliminary Amendment -21-
showing changes for
§ 371 Patent Application of PCT/EP00/02410
Markl, et al.
filed September 17, 2001

SEQ ID NO:108 (partial KLH2 domain h");

- (b) nucleic acid sequences which hybridize with the counter-strand of a nucleic acid sequence according to (a) and code for a polypeptide which has the immunological properties of at least one domain of a haemocyanin;
- (c) nucleic acid sequences which on the basis of the genetic code are degenerated to the DNA sequences defined under (a) and (b) and code for a polypeptide which has the immunological properties of at least one domain of a haemocyanin;
- (d) nucleic acid sequences which hybridize with one of the nucleic acid sequences described under (a) to (c) and the counter-strand of which codes for a polypeptide which has the immunological properties of at least one domain of a haemocyanin;
- (e) nucleic acid sequences which are at least 60% homologous to one of the nucleic acid sequences described under (a);
- (f) variants of the sequences described under (a) to (d), the variants containing additions, deletions, insertions or inversions with respect to the sequences described under (a) to (d) and coding for a polypeptide which has the immunological properties of at least one domain of haemocyanin;
and

Preliminary Amendment -22-
showing changes for
§ 371 Patent Application of PCT/EP00/02410
Markl, et al.
filed September 17, 2001

(g) combinations of several of the DNA sequences
described under (a) to (f) according to one of claims
1 to 6.

21. Haemocyanin polypeptide according to claim 20,
comprising at least one amino acid sequence selected
from the following group:

SEQ ID NO:25 (HtH1 domain a + signal peptide),
SEQ ID NO:26 (HtH1 domain b),
SEQ ID NO:27 (HtH1 domain c),
SEQ ID NO:28 (HtH1 domain d),
SEQ ID NO:29 (HtH1 domain e),
SEQ ID NO:30 (HtH1 domain f),
SEQ ID NO:31 (HtH1 domain g),
SEQ ID NO:32 (HtH1 domain h),
SEQ ID NO:33 (partial HtH2 domain b),
SEQ ID NO:34 (HtH2 domain c),
SEQ ID NO:35 (HtH2 domain d),
SEQ ID NO:36 (HtH2 domain e),
SEQ ID NO:37 (HtH2 domain f),
SEQ ID NO:38 (HtH2 domain g),
SEQ ID NO:39 (HtH2 domain h),
SEQ ID NO:40 (partial KLH1 domain b),
SEQ ID NO:41 (KLH1 domain c),
SEQ ID NO:42 (partial KLH1 domain d),
SEQ ID NO:43 (partial KLH1 domain e),
SEQ ID NO:44 (KLH2 domain b),
SEQ ID NO:45 (KLH2 domain c),
SEQ ID NO:46 (partial KLH2 domain d),
SEQ ID NO:47 (KLH2 domain g),

Preliminary Amendment -23-
showing changes for
§ 371 Patent Application of PCT/EP00/02410
Markl, et al.
filed September 17, 2001

SEQ ID NO:48 (partial KLH2 domain h),
SEQ ID NO:63 (HtH1 domain a' + signal peptide),
SEQ ID NO:64 (HtH1 domain h'),
SEQ ID NO:65 (partial HtH2 domain a),
SEQ ID NO:66 (HtH2 domain b'),
SEQ ID NO:67 (HtH2 domain d'),
SEQ ID NO:68 (HtH2 domain e'),
SEQ ID NO:69 (partial KLH1 domain b'),
SEQ ID NO:70 (KLH1 domain e'),
SEQ ID NO:71 (KLH1 domain f),
SEQ ID NO:72 (KLH1 domain g),
SEQ ID NO:73 (KLH1 domain h),
SEQ ID NO:74 (KLH2 domain b'),
SEQ ID NO:75 (KLH2 domain c'),
SEQ ID NO:76 (KLH2 domain d'),
SEQ ID NO:77 (KLH2 domain e),
SEQ ID NO:78 (KLH2 domain f),
SEQ ID NO:79 (KLH2 domain g'),

or a fragment of one of these sequences which has the immunological properties of at least one domain of a haemocyanin.

22. Recombinant haemocyanin polypeptide, obtainable by the process for the preparation of a haemocyanin polypeptide, wherein a nucleic acid molecule and/or a construct comprising said nucleic acid molecule is expressed in a suitable host cell and the protein is isolated, if appropriate, wherein said nucleic acid molecule comprising a nucleic acid molecule comprises a nucleic acid sequence which codes for a

Preliminary Amendment -24-
showing changes for
§ 371 Patent Application of PCT/EP00/02410
Markl, et al.
filed September 17, 2001

haemocyanin, a haemocyanin domain or a functional
fragment thereof with the immunological properties of
at least one domain of a haemocyanin, the nucleic
acid sequence being selected from:

(b) nucleic acid sequences which are selected from
the group consisting of the DNA sequences shown
below or the corresponding RNA sequences or which
contain these:

SEQ ID NO:1 (HtH1 domain a + signal peptide),
SEQ ID NO:2 (HtH1 domain b),
SEQ ID NO:3 (HtH1 domain c),
SEQ ID NO:4 (HtH1 domain d),
SEQ ID NO:5 (HtH1 domain e),
SEQ ID NO:6 (HtH1 domain f),
SEQ ID NO:7 (HtH1 domain g),
SEQ ID NO: 8 (HtH1 domain h),
SEQ ID NO:9 (partial HtH2 domain b),
SEQ ID NO:10 (HtH2 domain c),
SEQ ID NO:11 (HtH2 domain d),
SEQ ID NO:12 (HtH2 domain e),
SEQ ID NO:13 (HtH2 domain f),
SEQ ID NO:14 (HtH2 domain g),
SEQ ID NO:15 (HtH2 domain h),
SEQ ID NO:16 (partial KLH1 domain b),
SEQ ID NO:17 (KLH1 domain c),
SEQ ID NO:18 (KLH1 domain d),
SEQ ID NO:19 (partial KLH1 domain e),
SEQ ID NO:20 (KLH2 domain b),
SEQ ID NO:21 (KLH2 domain c),

Preliminary Amendment -25-
showing changes for
§ 371 Patent Application of PCT/EP00/02410
Markl, et al.
filed September 17, 2001

SEQ ID NO:22 (partial KLH2 domain d),
SEQ ID NO:23 (KLH2 domain g),
SEQ ID NO:24 (partial KLH2 domain h),
SEQ ID NO:49 (HtH1 domain a' + signal peptide),
SEQ ID NO:50 (partial HtH2 domain a),
SEQ ID NO:51 (HtH2 domain b'),
SEQ ID NO:52 (HtH2 domain d'),
SEQ ID NO:53 (HtH2 domain e'),
SEQ ID NO:54 (KLH1 domain e'),
SEQ ID NO:55 (KLH1 domain f),
SEQ ID NO:56 (KLH1 domain g),
SEQ ID NO:57 (KLH2 domain b'),
SEQ ID NO:58 (KLH2 domain c'),
SEQ ID NO:59 (KLH2 domain d'),
SEQ ID NO:60 (KLH2 domain e),
SEQ ID NO:61 (KLH2 domain f),
SEQ ID NO:62 (KLH2 domain g'),
SEQ ID NO:80 (HtH1 domain a" + signal peptide),
SEQ ID NO:81 (HtH1 domain b"),
SEQ ID NO:82 (HtH1 domain c"),
SEQ ID NO:83 (HtH1 domain d"),
SEQ ID NO:84 (HtH1 domain e"),
SEQ ID NO:85 (HtH1 domain f"),
SEQ ID NO:86 (HtH1 domain g"),
SEQ ID NO:87 (HtH1 domain h"),
SEQ ID NO:88 (partial HtH2 domain a"),
SEQ ID NO:89 (HtH2 domain b"),
SEQ ID NO:90 (HtH2 domain c"),
SEQ ID NO:91 (HtH2 domain d"),
SEQ ID NO:92 (HtH2 domain e"),
SEQ ID NO:93 (HtH2 domain f"),

Preliminary Amendment -26-
showing changes for
§ 371 Patent Application of PCT/EP00/02410
Markl, et al.
filed September 17, 2001

SEQ ID NO:94 (HtH2 domain g"),
SEQ ID NO:95 (HtH2 domain h"),
SEQ ID NO:96 (partial KLH1 domain b"),
SEQ ID NO:97 (KLH1 domain c"),
SEQ ID NO:98 (KLH1 domain d"),
SEQ ID NO:99 (KLH1 domain e"),
SEQ ID NO:100 (KLH1 domain f"),
SEQ ID NO:101 (KLH1 domain g"),
SEQ ID NO:102 (KLH2 domain b"),
SEQ ID NO:103 (KLH2 domain c"),
SEQ ID NO:104 (KLH2 domain d"),
SEQ ID NO:105 (KLH2 domain e"),
SEQ ID NO:106 (KLH2 domain f"),
SEQ ID NO:107 (KLH2 domain g"),
SEQ ID NO:108 (partial KLH2 domain h");

- (b) nucleic acid sequences which hybridize with the counter-strand of a nucleic acid sequence according to (a) and code for a polypeptide which has the immunological properties of at least one domain of a haemocyanin;
- (c) nucleic acid sequences which on the basis of the genetic code are degenerated to the DNA sequences defined under (a) and (b) and code for a polypeptide which has the immunological properties of at least one domain of a haemocyanin;
- (d) nucleic acid sequences which hybridize with one of the nucleic acid sequences described under (a) to (c) and the counter-strand of which codes for a polypeptide which has the immunological properties

Preliminary Amendment -27-
showing changes for
§ 371 Patent Application of PCT/EP00/02410
Markl, et al.
filed September 17, 2001

of at least one domain of a haemocyanin;

(e) nucleic acid sequences which are at least 60%
homologous to one of the nucleic acid sequences
described under (a);

(f) variants of the sequences described under (a) to
(d), the variants containing additions, deletions,
insertions or inversions with respect to the
sequences described under (a) to (d) and coding
for a polypeptide which has the immunological
properties of at least one domain of haemocyanin;
and

(g) combinations of several of the DNA sequences
described under (a) to (f) according to one of claims
16 to 19 or modifications thereof.

23. Recombinant haemocyanin polypeptide according to
claim 22, **characterized in that** it comprises the
sequences SEQ ID NO: 25 to 32 and is haemocyanin 1
from *Haliotis tuberculata*, it being possible for the
sequence with SEQ ID NO:25 to be replaced by SEQ ID
NO:63 and/or SEQ ID NO:32 to be replaced by SEQ ID
NO:64.

24. Recombinant haemocyanin polypeptide according to
claim 22, **characterized in that** it comprises either
the sequences SEQ ID NO: 33 to 39 or the sequences
SEQ ID NO:65, 66, 34-39 and is haemocyanin 2 from
Haliotis tuberculata, it being possible in each case

Preliminary Amendment -28-
showing changes for
§ 371 Patent Application of PCT/EP00/02410
Markl, et al.
filed September 17, 2001

for SEQ ID NO:35 to be replaced by SEQ ID NO:67
and/or SEQ ID NO:36 to be replaced by SEQ ID NO:68.

25. Recombinant haemocyanin polypeptide according to
claim 23, **characterized in that** it has an apparent
molecular weight of 370 kDa in SDS-PAGE under
reducing conditions.

26. Recombinant haemocyanin polypeptide according to
claim 24, **characterized in that** it has an apparent
molecular weight of 370 kDa in SDS-PAGE under
reducing conditions.

27. Recombinant haemocyanin polypeptide according to
claim 21, **characterized in that** the haemocyanin
polypeptide comprises either the sequences SEQ ID NO:
40 to 43 or the sequences SEQ ID NO:40 to 43 and SEQ
ID NO:71 to 73 and is KLH1 from *Megathura crenulata*,
it being possible in each case the for sequence with
SEQ ID NO:40 to be replaced by SEQ ID NO:66 and/or
SEQ ID NO:43 to be replaced by SEQ ID NO:70.

28. Recombinant haemocyanin polypeptide according to
claim 21, **characterized in that** the haemocyanin
polypeptide comprises either the sequences SEQ ID NO:
44 to 48 or the sequences SEQ ID NO:44 to 46, 77, 78,
47, 48 and is KLH2 from *Megathura crenulata*, in being
possible in each case for the sequence with SEQ ID
NO:44 to be replaced by SEQ ID NO:74, SEQ ID NO:45 to
be replaced by SEQ ID NO:75, SEQ ID NO:46 to be
replaced by SEQ ID NO:76 and/or SEQ ID NO:47 to be

Preliminary Amendment -29-
showing changes for
§ 371 Patent Application of PCT/EP00/02410
Markl, et al.
filed September 17, 2001

replaced by SEQ ID NO:79.

29. Recombinant haemocyanin polypeptide according to ~~one of claims 20 to 28~~, **characterized in that** it is bonded covalently to viruses, virus constituents, bacteria, bacteria constituents, DNA, DNA constituents, inorganic or organic molecules, such as e.g. carbohydrates, peptides and/or glycoproteins.

30. Recombinant haemocyanin polypeptide according to ~~one of claims 20 to 29~~, **characterized in that** the haemocyanin polypeptide is non-glycosylated.

31. Recombinant haemocyanin polypeptide according to ~~one of claims 20 to 29~~, **characterized in that** the haemocyanin polypeptide is glycosylated.

32. Pharmaceutical composition, comprising a nucleic acid molecule ~~according to one of claims 1 to 6~~ and/or a construct comprising said nucleic acid molecule according to one of claims 7 to 12 and physiologically tolerated additives, wherein said nucleic acid molecule comprises a nucleic acid sequence which codes for a haemocyanin, a haemocyanin domain or a functional fragment thereof with the immunological properties of at least one domain of a haemocyanin, the nucleic acid sequence being selected from:

(b) nucleic acid sequences which are selected from the group consisting of the DNA sequences shown

Preliminary Amendment -30-
showing changes for
§ 371 Patent Application of PCT/EP00/02410
Markl, et al.
filed September 17, 2001

below or the corresponding RNA sequences or which
contain these:

SEQ ID NO:1 (HtH1 domain a + signal peptide),
SEQ ID NO:2 (HtH1 domain b),
SEQ ID NO:3 (HtH1 domain c),
SEQ ID NO:4 (HtH1 domain d),
SEQ ID NO:5 (HtH1 domain e),
SEQ ID NO:6 (HtH1 domain f),
SEQ ID NO:7 (HtH1 domain g),
SEQ ID NO: 8 (HtH1 domain h),
SEQ ID NO:9 (partial HtH2 domain b),
SEQ ID NO:10 (HtH2 domain c),
SEQ ID NO:11 (HtH2 domain d),
SEQ ID NO:12 (HtH2 domain e),
SEQ ID NO:13 (HtH2 domain f),
SEQ ID NO:14 (HtH2 domain g),
SEQ ID NO:15 (HtH2 domain h),
SEQ ID NO:16 (partial KLH1 domain b),
SEQ ID NO:17 (KLH1 domain c),
SEQ ID NO:18 (KLH1 domain d),
SEQ ID NO:19 (partial KLH1 domain e),
SEQ ID NO:20 (KLH2 domain b),
SEQ ID NO:21 (KLH2 domain c),
SEQ ID NO:22 (partial KLH2 domain d),
SEQ ID NO:23 (KLH2 domain g),
SEQ ID NO:24 (partial KLH2 domain h),
SEQ ID NO:49 (HtH1 domain a' + signal peptide),
SEQ ID NO:50 (partial HtH2 domain a),
SEQ ID NO:51 (HtH2 domain b'),
SEQ ID NO:52 (HtH2 domain d'),

Preliminary Amendment -31-
showing changes for
§ 371 Patent Application of PCT/EP00/02410
Markl, et al.
filed September 17, 2001

SEQ ID NO:53 (HtH2 domain e'),
SEQ ID NO:54 (KLH1 domain e'),
SEQ ID NO:55 (KLH1 domain f),
SEQ ID NO:56 (KLH1 domain g),
SEQ ID NO:57 (KLH2 domain b'),
SEQ ID NO:58 (KLH2 domain c'),
SEQ ID NO:59 (KLH2 domain d'),
SEQ ID NO:60 (KLH2 domain e),
SEQ ID NO:61 (KLH2 domain f),
SEQ ID NO:62 (KLH2 domain g'),
SEQ ID NO:80 (HtH1 domain a" + signal peptide),
SEQ ID NO:81 (HtH1 domain b"),
SEQ ID NO:82 (HtH1 domain c"),
SEQ ID NO:83 (HtH1 domain d"),
SEQ ID NO:84 (HtH1 domain e"),
SEQ ID NO:85 (HtH1 domain f"),
SEQ ID NO:86 (HtH1 domain g"),
SEQ ID NO:87 (HtH1 domain h"),
SEQ ID NO:88 (partial HtH2 domain a"),
SEQ ID NO:89 (HtH2 domain b"),
SEQ ID NO:90 (HtH2 domain c"),
SEQ ID NO:91 (HtH2 domain d"),
SEQ ID NO:92 (HtH2 domain e"),
SEQ ID NO:93 (HtH2 domain f"),
SEQ ID NO:94 (HtH2 domain g"),
*SEQ ID NO:95 (HtH2 domain h"),
SEQ ID NO:96 (partial KLH1 domain b"),
SEQ ID NO:97 (KLH1 domain c"),
SEQ ID NO:98 (KLH1 domain d"),
SEQ ID NO:99 (KLH1 domain e"),
SEQ ID NO:100 (KLH1 domain f"),

Preliminary Amendment -32-
showing changes for
§ 371 Patent Application of PCT/EP00/02410
Markl, et al.
filed September 17, 2001

SEQ ID NO:101 (KLH1 domain g"),
SEQ ID NO:102 (KLH2 domain b"),
SEQ ID NO:103 (KLH2 domain c"),
SEQ ID NO:104 (KLH2 domain d"),
SEQ ID NO:105 (KLH2 domain e"),
SEQ ID NO:106 (KLH2 domain f"),
SEQ ID NO:107 (KLH2 domain g"),
SEQ ID NO:108 (partial KLH2 domain h");

- (b) nucleic acid sequences which hybridize with the counter-strand of a nucleic acid sequence according to (a) and code for a polypeptide which has the immunological properties of at least one domain of a haemocyanin;
- (c) nucleic acid sequences which on the basis of the genetic code are degenerate to the DNA sequences defined under (a) and (b) and code for a polypeptide which has the immunological properties of at least one domain of a haemocyanin;
- (d) nucleic acid sequences which hybridize with one of the nucleic acid sequences described under (a) to (c) and the counter-strand of which codes for a polypeptide which has the immunological properties of at least one domain of a haemocyanin;
- (e) nucleic acid sequences which are at least 60% homologous to one of the nucleic acid sequences described under (a);
- (f) variants of the sequences described under (a) to

Preliminary Amendment -33-
showing changes for
§ 371 Patent Application of PCT/EP00/02410
Markl, et al.
filed September 17, 2001

(d), the variants containing additions, deletions, insertions or inversions with respect to the sequences described under (a) to (d) and coding for a polypeptide which has the immunological properties of at least one domain of haemocyanin; and

(g) combinations of several of the DNA sequences described under (a) to (f).

33. Pharmaceutical composition according to claim 32, **characterized in that** it is used for gene therapy treatment of tumours.

34. Pharmaceutical composition, comprising a haemocyanin polypeptide according to ~~one of~~ claims 20 ~~to 31~~ and physiologically tolerated additives, wherein said haemocyanin polypeptide comprises an amino acid sequence which is coded by one or more of the nucleic acid molecule comprising a nucleic acid sequence which codes for a haemocyanin, a haemocyanin domain or a functional fragment thereof with the immunological properties of at least one domain of a haemocyanin, the nucleic acid sequence being selected from:

(b) nucleic acid sequences which are selected from the group consisting of the DNA sequences shown below or the corresponding RNA sequences or which contain these:

Preliminary Amendment -34-
showing changes for
§ 371 Patent Application of PCT/EP00/02410
Markl, et al.
filed September 17, 2001

SEQ ID NO:1 (HtH1 domain a + signal peptide),
SEQ ID NO:2 (HtH1 domain b),
SEQ ID NO:3 (HtH1 domain c),
SEQ ID NO:4 (HtH1 domain d),
SEQ ID NO:5 (HtH1 domain e),
SEQ ID NO:6 (HtH1 domain f),
SEQ ID NO:7 (HtH1 domain g),
SEQ ID NO: 8 (HtH1 domain h),
SEQ ID NO:9 (partial HtH2 domain b),
SEQ ID NO:10 (HtH2 domain c),
SEQ ID NO:11 (HtH2 domain d),
SEQ ID NO:12 (HtH2 domain e),
SEQ ID NO:13 (HtH2 domain f),
SEQ ID NO:14 (HtH2 domain g),
SEQ ID NO:15 (HtH2 domain h),
SEQ ID NO:16 (partial KLH1 domain b),
SEQ ID NO:17 (KLH1 domain c),
SEQ ID NO:18 (KLH1 domain d),
SEQ ID NO:19 (partial KLH1 domain e),
SEQ ID NO:20 (KLH2 domain b),
SEQ ID NO:21 (KLH2 domain c),
SEQ ID NO:22 (partial KLH2 domain d),
SEQ ID NO:23 (KLH2 domain g),
SEQ ID NO:24 (partial KLH2 domain h),
SEQ ID NO:49 (HtH1 domain a' + signal peptide),
SEQ ID NO:50 (partial HtH2 domain a),
SEQ ID NO:51 (HtH2 domain b'),
SEQ ID NO:52 (HtH2 domain d'),
SEQ ID NO:53 (HtH2 domain e'),
SEQ ID NO:54 (KLH1 domain e'),
SEQ ID NO:55 (KLH1 domain f),

Preliminary Amendment -35-
showing changes for
§ 371 Patent Application of PCT/EP00/02410
Markl, et al.
filed September 17, 2001

SEQ ID NO:56 (KLH1 domain g),
SEQ ID NO:57 (KLH2 domain b'),
SEQ ID NO:58 (KLH2 domain c'),
SEQ ID NO:59 (KLH2 domain d'),
SEQ ID NO:60 (KLH2 domain e),
SEQ ID NO:61 (KLH2 domain f),
SEQ ID NO:62 (KLH2 domain g'),
SEQ ID NO:80 (HtH1 domain a" + signal peptide),
SEQ ID NO:81 (HtH1 domain b"),
SEQ ID NO:82 (HtH1 domain c"),
SEQ ID NO:83 (HtH1 domain d"),
SEQ ID NO:84 (HtH1 domain e"),
SEQ ID NO:85 (HtH1 domain f"),
SEQ ID NO:86 (HtH1 domain g"),
SEQ ID NO:87 (HtH1 domain h"),
SEQ ID NO:88 (partial HtH2 domain a"),
SEQ ID NO:89 (HtH2 domain b"),
SEQ ID NO:90 (HtH2 domain c"),
SEQ ID NO:91 (HtH2 domain d"),
SEQ ID NO:92 (HtH2 domain e"),
SEQ ID NO:93 (HtH2 domain f"),
SEQ ID NO:94 (HtH2 domain g"),
SEQ ID NO:95 (HtH2 domain h"),
SEQ ID NO:96 (partial KLH1 domain b"),
SEQ ID NO:97 (KLH1 domain c"),
SEQ ID NO:98 (KLH1 domain d"),
SEQ ID NO:99 (KLH1 domain e"),
SEQ ID NO:100 (KLH1 domain f"),
SEQ ID NO:101 (KLH1 domain g"),
SEQ ID NO:102 (KLH2 domain b"),
SEQ ID NO:103 (KLH2 domain c"),

Preliminary Amendment -36-
showing changes for
§ 371 Patent Application of PCT/EP00/02410
Markl, et al.
filed September 17, 2001

SEQ ID NO:104 (KLH2 domain d"),
SEQ ID NO:105 (KLH2 domain e"),
SEQ ID NO:106 (KLH2 domain f"),
SEQ ID NO:107 (KLH2 domain g"),
SEQ ID NO:108 (partial KLH2 domain h");

- (b) nucleic acid sequences which hybridize with the counter-strand of a nucleic acid sequence according to (a) and code for a polypeptide which has the immunological properties of at least one domain of a haemocyanin;
- (c) nucleic acid sequences which on the basis of the genetic code are degenerated to the DNA sequences defined under (a) and (b) and code for a polypeptide which has the immunological properties of at least one domain of a haemocyanin;
- (d) nucleic acid sequences which hybridize with one of the nucleic acid sequences described under (a) to (c) and the counter-strand of which codes for a polypeptide which has the immunological properties of at least one domain of a haemocyanin;
- (e) nucleic acid sequences which are at least 60% homologous to one of the nucleic acid sequences described under (a);
- (f) variants of the sequences described under (a) to (d), the variants containing additions, deletions, insertions or inversions with respect to the sequences described under (a) to (d) and coding

Preliminary Amendment -37-
showing changes for
§ 371 Patent Application of PCT/EP00/02410
Markl, et al.
filed September 17, 2001

for a polypeptide which has the immunological
properties of at least one domain of haemocyanin;
and

(g) combinations of several of the DNA sequences
described under (a) to (f).

35. Pharmaceutical composition according to claim
34, **characterized in that** it is used as an
antiparasitic composition, antiviral composition or
as an antitumour composition.

36. Pharmaceutical composition according to claim
34, **characterized in that** it is used for treatment of
one of the following diseases: schistosomiasis, high
blood pressure, surface bladder carcinomas,
epithelial carcinomas, ovarian carcinoma, mammary
carcinoma, bronchial carcinoma and colorectal
carcinoma.

37. Pharmaceutical composition according to claim
34, **characterized in that** it is used as a vaccine.

38. Pharmaceutical composition according to claim
34, **characterized in that** it is used for prevention
of cocaine abuse.

39. Use of a haemocyanin polypeptide ~~according to~~
~~one of claims 20 to 31~~ as a carrier substance for
medicaments, wherein said haemocyanin polypeptide
comprises an amino acid sequence which is coded by

Preliminary Amendment -38-
showing changes for
§ 371 Patent Application of PCT/EP00/02410
Markl, et al.
filed September 17, 2001

one or more of the nucleic acid molecule comprising a
nucleic acid sequence which codes for a haemocyanin,
a haemocyanin domain or a functional fragment thereof
with the immunological properties of at least one
domain of a haemocyanin, the nucleic acid sequence
being selected from:

(b) nucleic acid sequences which are selected from
the group consisting of the DNA sequences shown
below or the corresponding RNA sequences or which
contain these:

SEQ ID NO:1 (HtH1 domain a + signal peptide),
SEQ ID NO:2 (HtH1 domain b),
SEQ ID NO:3 (HtH1 domain c),
SEQ ID NO:4 (HtH1 domain d),
SEQ ID NO:5 (HtH1 domain e),
SEQ ID NO:6 (HtH1 domain f),
SEQ ID NO:7 (HtH1 domain g),
SEQ ID NO: 8 (HtH1 domain h),
SEQ ID NO:9 (partial HtH2 domain b),
SEQ ID NO:10 (HtH2 domain c),
SEQ ID NO:11 (HtH2 domain d),
SEQ ID NO:12 (HtH2 domain e),
SEQ ID NO:13 (HtH2 domain f),
SEQ ID NO:14 (HtH2 domain g),
SEQ ID NO:15 (HtH2 domain h),
SEQ ID NO:16 (partial KLH1 domain b),
SEQ ID NO:17 (KLH1 domain c),
SEQ ID NO:18 (KLH1 domain d),
SEQ ID NO:19 (partial KLH1 domain e),

Preliminary Amendment -39-
showing changes for
§ 371 Patent Application of PCT/EP00/02410
Markl, et al.
filed September 17, 2001

SEQ ID NO:20 (KLH2 domain b),
SEQ ID NO:21 (KLH2 domain c),
SEQ ID NO:22 (partial KLH2 domain d),
SEQ ID NO:23 (KLH2 domain g),
SEQ ID NO:24 (partial KLH2 domain h),
SEQ ID NO:49 (HtH1 domain a' + signal peptide),
SEQ ID NO:50 (partial HtH2 domain a),
SEQ ID NO:51 (HtH2 domain b'),
SEQ ID NO:52 (HtH2 domain d'),
SEQ ID NO:53 (HtH2 domain e'),
SEQ ID NO:54 (KLH1 domain e'),
SEQ ID NO:55 (KLH1 domain f),
SEQ ID NO:56 (KLH1 domain g),
SEQ ID NO:57 (KLH2 domain b'),
SEQ ID NO:58 (KLH2 domain c'),
SEQ ID NO:59 (KLH2 domain d'),
SEQ ID NO:60 (KLH2 domain e),
SEQ ID NO:61 (KLH2 domain f),
SEQ ID NO:62 (KLH2 domain g'),
SEQ ID NO:80 (HtH1 domain a" + signal peptide),
SEQ ID NO:81 (HtH1 domain b"),
SEQ ID NO:82 (HtH1 domain c"),
SEQ ID NO:83 (HtH1 domain d"),
SEQ ID NO:84 (HtH1 domain e"),
SEQ ID NO:85 (HtH1 domain f"),
SEQ ID NO:86 (HtH1 domain g"),
SEQ ID NO:87 (HtH1 domain h"),
SEQ ID NO:88 (partial HtH2 domain a"),
SEQ ID NO:89 (HtH2 domain b"),
SEQ ID NO:90 (HtH2 domain c"),
SEQ ID NO:91 (HtH2 domain d"),

Preliminary Amendment -40-
showing changes for
§ 371 Patent Application of PCT/EP00/02410
Markl, et al.
filed September 17, 2001

SEQ ID NO:92 (HtH2 domain e"),
SEQ ID NO:93 (HtH2 domain f"),
SEQ ID NO:94 (HtH2 domain g"),
SEQ ID NO:95 (HtH2 domain h"),
SEQ ID NO:96 (partial KLH1 domain b"),
SEQ ID NO:97 (KLH1 domain c"),
SEQ ID NO:98 (KLH1 domain d"),
SEQ ID NO:99 (KLH1 domain e"),
SEQ ID NO:100 (KLH1 domain f"),
SEQ ID NO:101 (KLH1 domain g"),
SEQ ID NO:102 (KLH2 domain b"),
SEQ ID NO:103 (KLH2 domain c"),
SEQ ID NO:104 (KLH2 domain d"),
SEQ ID NO:105 (KLH2 domain e"),
SEQ ID NO:106 (KLH2 domain f"),
SEQ ID NO:107 (KLH2 domain g"),
SEQ ID NO:108 (partial KLH2 domain h");

- (b) nucleic acid sequences which hybridize with the counter-strand of a nucleic acid sequence according to (a) and code for a polypeptide which has the immunological properties of at least one domain of a haemocyanin;
- (c) nucleic acid sequences which on the basis of the genetic code are degenerated to the DNA sequences defined under (a) and (b) and code for a polypeptide which has the immunological properties of at least one domain of a haemocyanin;
- (d) nucleic acid sequences which hybridize with one of the nucleic acid sequences described under (a)

Preliminary Amendment -41-
showing changes for
§ 371 Patent Application of PCT/EP00/02410
Markl, et al.
filed September 17, 2001

to (c) and the counter-strand of which codes for a polypeptide which has the immunological properties of at least one domain of a haemocyanin;

(e) nucleic acid sequences which are at least 60% homologous to one of the nucleic acid sequences described under (a);

(f) variants of the sequences described under (a) to (d), the variants containing additions, deletions, insertions or inversions with respect to the sequences described under (a) to (d) and coding for a polypeptide which has the immunological properties of at least one domain of haemocyanin; and

(g) combinations of several of the DNA sequences described under (a) to (f).

40. Liposome, comprising a nucleic acid molecule ~~according to one of claims 1 to 6~~, a construct ~~comprising said nucleic acid molecule according to one of claims 7 to 12~~ and/or a haemocyanin polypeptide ~~encoded by said nucleic acid molecule according to one of claims 20 to 31~~, wherein said nucleic acid molecule comprises a nucleic acid sequence which codes for a haemocyanin, a haemocyanin domain or a functional fragment thereof with the immunological properties of at least one domain of a haemocyanin, the nucleic acid sequence being selected from:

Preliminary Amendment -42-
showing changes for
§ 371 Patent Application of PCT/EP00/02410
Markl, et al.
filed September 17, 2001

(b) nucleic acid sequences which are selected from
the group consisting of the DNA sequences shown
below or the corresponding RNA sequences or which
contain these:

SEQ ID NO:1 (HtH1 domain a + signal peptide),
SEQ ID NO:2 (HtH1 domain b),
SEQ ID NO:3 (HtH1 domain c),
SEQ ID NO:4 (HtH1 domain d),
SEQ ID NO:5 (HtH1 domain e),
SEQ ID NO:6 (HtH1 domain f),
SEQ ID NO:7 (HtH1 domain g),
SEQ ID NO: 8 (HtH1 domain h),
SEQ ID NO:9 (partial HtH2 domain b),
SEQ ID NO:10 (HtH2 domain c),
SEQ ID NO:11 (HtH2 domain d),
SEQ ID NO:12 (HtH2 domain e),
SEQ ID NO:13 (HtH2 domain f),
SEQ ID NO:14 (HtH2 domain g),
SEQ ID NO:15 (HtH2 domain h),
SEQ ID NO:16 (partial KLH1 domain b),
SEQ ID NO:17 (KLH1 domain c),
SEQ ID NO:18 (KLH1 domain d),
SEQ ID NO:19 (partial KLH1 domain e),
SEQ ID NO:20 (KLH2 domain b),
SEQ ID NO:21 (KLH2 domain c),
SEQ ID NO:22 (partial KLH2 domain d),
SEQ ID NO:23 (KLH2 domain g),
SEQ ID NO:24 (partial KLH2 domain h),
SEQ ID NO:49 (HtH1 domain a' + signal peptide),
SEQ ID NO:50 (partial HtH2 domain a),

Preliminary Amendment -43-
showing changes for
§ 371 Patent Application of PCT/EP00/02410
Markl, et al.
filed September 17, 2001

SEQ ID NO:51 (HtH2 domain b'),
SEQ ID NO:52 (HtH2 domain d'),
SEQ ID NO:53 (HtH2 domain e'),
SEQ ID NO:54 (KLH1 domain e'),
SEQ ID NO:55 (KLH1 domain f),
SEQ ID NO:56 (KLH1 domain g),
SEQ ID NO:57 (KLH2 domain b'),
SEQ ID NO:58 (KLH2 domain c'),
SEQ ID NO:59 (KLH2 domain d'),
SEQ ID NO:60 (KLH2 domain e),
SEQ ID NO:61 (KLH2 domain f),
SEQ ID NO:62 (KLH2 domain g'),
SEQ ID NO:80 (HtH1 domain a" + signal peptide),
SEQ ID NO:81 (HtH1 domain b"),
SEQ ID NO:82 (HtH1 domain c"),
SEQ ID NO:83 (HtH1 domain d"),
SEQ ID NO:84 (HtH1 domain e"),
SEQ ID NO:85 (HtH1 domain f"),
SEQ ID NO:86 (HtH1 domain g"),
SEQ ID NO:87 (HtH1 domain h"),
SEQ ID NO:88 (partial HtH2 domain a"),
SEQ ID NO:89 (HtH2 domain b"),
SEQ ID NO:90 (HtH2 domain c"),
SEQ ID NO:91 (HtH2 domain d"),
SEQ ID NO:92 (HtH2 domain e"),
SEQ ID NO:93 (HtH2 domain f"),
SEQ ID NO:94 (HtH2 domain g"),
SEQ ID NO:95 (HtH2 domain h"),
SEQ ID NO:96 (partial KLH1 domain b"),
SEQ ID NO:97 (KLH1 domain c"),
SEQ ID NO:98 (KLH1 domain d"),

Preliminary Amendment -44-
showing changes for
§ 371 Patent Application of PCT/EP00/02410
Markl, et al.
filed September 17, 2001

SEQ ID NO:99 (KLH1 domain e"),
SEQ ID NO:100 (KLH1 domain f"),
SEQ ID NO:101 (KLH1 domain g"),
SEQ ID NO:102 (KLH2 domain b"),
SEQ ID NO:103 (KLH2 domain c"),
SEQ ID NO:104 (KLH2 domain d"),
SEQ ID NO:105 (KLH2 domain e"),
SEQ ID NO:106 (KLH2 domain f"),
SEQ ID NO:107 (KLH2 domain g"),
SEQ ID NO:108 (partial KLH2 domain h");

- (b) nucleic acid sequences which hybridize with the counter-strand of a nucleic acid sequence according to (a) and code for a polypeptide which has the immunological properties of at least one domain of a haemocyanin;
- (c) nucleic acid sequences which on the basis of the genetic code are degenerate to the DNA sequences defined under (a) and (b) and code for a polypeptide which has the immunological properties of at least one domain of a haemocyanin;
- (d) nucleic acid sequences which hybridize with one of the nucleic acid sequences described under (a) to (c) and the counter-strand of which codes for a polypeptide which has the immunological properties of at least one domain of a haemocyanin;
- (e) nucleic acid sequences which are at least 60% homologous to one of the nucleic acid sequences described under (a);

(f) variants of the sequences described under (a) to (d), the variants containing additions, deletions, insertions or inversions with respect to the sequences described under (a) to (d) and coding for a polypeptide which has the immunological properties of at least one domain of haemocyanin; and

(g) combinations of several of the DNA sequences described under (a) to (f).

41. Liposome according to claim 40, **characterized in that** the liposome furthermore comprises cell recognition molecules.

42. Antibodies, obtainable by immunization of a test animal with ~~at~~ the recombinant haemocyanin polypeptide comprising an amino acid sequence which is coded by one or more of the nucleic acid molecule comprising a nucleic acid sequence which codes for a haemocyanin, a haemocyanin domain or a functional fragment thereof with the immunological properties of at least one domain of a haemocyanin, the nucleic acid sequence being selected from:

(b) nucleic acid sequences which are selected from the group consisting of the DNA sequences shown below or the corresponding RNA sequences or which contain these:

Preliminary Amendment -46-
showing changes for
§ 371 Patent Application of PCT/EP00/02410
Markl, et al.
filed September 17, 2001

SEQ ID NO:1 (HtH1 domain a + signal peptide),
SEQ ID NO:2 (HtH1 domain b),
SEQ ID NO:3 (HtH1 domain c),
SEQ ID NO:4 (HtH1 domain d),
SEQ ID NO:5 (HtH1 domain e),
SEQ ID NO:6 (HtH1 domain f),
SEQ ID NO:7 (HtH1 domain g),
SEQ ID NO: 8 (HtH1 domain h),
SEQ ID NO:9 (partial HtH2 domain b),
SEQ ID NO:10 (HtH2 domain c),
SEQ ID NO:11 (HtH2 domain d),
SEQ ID NO:12 (HtH2 domain e),
SEQ ID NO:13 (HtH2 domain f),
SEQ ID NO:14 (HtH2 domain g),
SEQ ID NO:15 (HtH2 domain h),
SEQ ID NO:16 (partial KLH1 domain b),
SEQ ID NO:17 (KLH1 domain c),
SEQ ID NO:18 (KLH1 domain d),
SEQ ID NO:19 (partial KLH1 domain e),
SEQ ID NO:20 (KLH2 domain b),
SEQ ID NO:21 (KLH2 domain c),
SEQ ID NO:22 (partial KLH2 domain d),
SEQ ID NO:23 (KLH2 domain g),
SEQ ID NO:24 (partial KLH2 domain h),
SEQ ID NO:49 (HtH1 domain a' + signal peptide),
SEQ ID NO:50 (partial HtH2 domain a),
SEQ ID NO:51 (HtH2 domain b'),
SEQ ID NO:52 (HtH2 domain d'),
SEQ ID NO:53 (HtH2 domain e'),
SEQ ID NO:54 (KLH1 domain e'),
SEQ ID NO:55 (KLH1 domain f),

Preliminary Amendment -47-
showing changes for
§ 371 Patent Application of PCT/EP00/02410
Markl, et al.
filed September 17, 2001

SEQ ID NO:56 (KLH1 domain g),
SEQ ID NO:57 (KLH2 domain b'),
SEQ ID NO:58 (KLH2 domain c'),
SEQ ID NO:59 (KLH2 domain d'),
SEQ ID NO:60 (KLH2 domain e),
SEQ ID NO:61 (KLH2 domain f),
SEQ ID NO:62 (KLH2 domain g'),
SEQ ID NO:80 (HtH1 domain a" + signal peptide),
SEQ ID NO:81 (HtH1 domain b"),
SEQ ID NO:82 (HtH1 domain c"),
SEQ ID NO:83 (HtH1 domain d"),
SEQ ID NO:84 (HtH1 domain e"),
SEQ ID NO:85 (HtH1 domain f"),
SEQ ID NO:86 (HtH1 domain g"),
SEQ ID NO:87 (HtH1 domain h"),
SEQ ID NO:88 (partial HtH2 domain a"),
SEQ ID NO:89 (HtH2 domain b"),
SEQ ID NO:90 (HtH2 domain c"),
SEQ ID NO:91 (HtH2 domain d"),
SEQ ID NO:92 (HtH2 domain e"),
SEQ ID NO:93 (HtH2 domain f"),
SEQ ID NO:94 (HtH2 domain g"),
SEQ ID NO:95 (HtH2 domain h"),
SEQ ID NO:96 (partial KLH1 domain b"),
SEQ ID NO:97 (KLH1 domain c"),
SEQ ID NO:98 (KLH1 domain d"),
SEQ ID NO:99 (KLH1 domain e"),
SEQ ID NO:100 (KLH1 domain f"),
SEQ ID NO:101 (KLH1 domain g"),
SEQ ID NO:102 (KLH2 domain b"),
SEQ ID NO:103 (KLH2 domain c"),

Preliminary Amendment -48-
showing changes for
§ 371 Patent Application of PCT/EP00/02410
Markl, et al.
filed September 17, 2001

SEQ ID NO:104 (KLH2 domain d"),
SEQ ID NO:105 (KLH2 domain e"),
SEQ ID NO:106 (KLH2 domain f"),
SEQ ID NO:107 (KLH2 domain g"),
SEQ ID NO:108 (partial KLH2 domain h");

- (b) nucleic acid sequences which hybridize with the counter-strand of a nucleic acid sequence according to (a) and code for a polypeptide which has the immunological properties of at least one domain of a haemocyanin;
- (c) nucleic acid sequences which on the basis of the genetic code are degenerated to the DNA sequences defined under (a) and (b) and code for a polypeptide which has the immunological properties of at least one domain of a haemocyanin;
- (d) nucleic acid sequences which hybridize with one of the nucleic acid sequences described under (a) to (c) and the counter-strand of which codes for a polypeptide which has the immunological properties of at least one domain of a haemocyanin;
- (e) nucleic acid sequences which are at least 60% homologous to one of the nucleic acid sequences described under (a);
- (f) variants of the sequences described under (a) to (d), the variants containing additions, deletions, insertions or inversions with respect to the sequences described under (a) to (d) and coding

Preliminary Amendment -49-
showing changes for
§ 371 Patent Application of PCT/EP00/02410
Markl, et al.
filed September 17, 2001

for a polypeptide which has the immunological
properties of at least one domain of haemocyanin;
and

(g) combinations of several of the DNA sequences
described under (a) to (f) according to one of claims
20 to 31.

43. Screening method for identification of tumour-
specific DNA in a cell, comprising:

A.a) bringing cell DNA and/or cell protein into
contact with a probe comprising a nucleic acid
molecule sequence according to one of claims 1 to 6
and/or the antibody obtainable by immunization of a
test animal with a recombinant haemocyanin
polypeptide comprising an amino acid sequence which
is coded by one or more of said nucleic acid
molecules, wherein said nucleic acid molecule
comprises a nucleic acid sequence which codes for a
haemocyanin, a haemocyanin domain or a functional
fragment thereof with the immunological properties of
at least one domain of a haemocyanin, the nucleic
acid sequence being selected from:

(b) nucleic acid sequences which are selected from
the group consisting of the DNA sequences shown
below or the corresponding RNA sequences or which
contain these:

SEQ ID NO:1 (HtH1 domain a + signal peptide),
SEQ ID NO:2 (HtH1 domain b),

Preliminary Amendment -50-
showing changes for
§ 371 Patent Application of PCT/EP00/02410
Markl, et al.
filed September 17, 2001

SEQ ID NO:3 (HtH1 domain c),
SEQ ID NO:4 (HtH1 domain d),
SEQ ID NO:5 (HtH1 domain e),
SEQ ID NO:6 (HtH1 domain f),
SEQ ID NO:7 (HtH1 domain g),
SEQ ID NO: 8 (HtH1 domain h),
SEQ ID NO:9 (partial HtH2 domain b),
SEQ ID NO:10 (HtH2 domain c),
SEQ ID NO:11 (HtH2 domain d),
SEQ ID NO:12 (HtH2 domain e),
SEQ ID NO:13 (HtH2 domain f),
SEQ ID NO:14 (HtH2 domain g),
SEQ ID NO:15 (HtH2 domain h),
SEQ ID NO:16 (partial KLH1 domain b),
SEQ ID NO:17 (KLH1 domain c),
SEQ ID NO:18 (KLH1 domain d),
SEQ ID NO:19 (partial KLH1 domain e),
SEQ ID NO:20 (KLH2 domain b),
SEQ ID NO:21 (KLH2 domain c),
SEQ ID NO:22 (partial KLH2 domain d),
SEQ ID NO:23 (KLH2 domain g),
SEQ ID NO:24 (partial KLH2 domain h),
SEQ ID NO:49 (HtH1 domain a' + signal peptide),
SEQ ID NO:50 (partial HtH2 domain a),
SEQ ID NO:51 (HtH2 domain b'),
SEQ ID NO:52 (HtH2 domain d'),
SEQ ID NO:53 (HtH2 domain e'),
SEQ ID NO:54 (KLH1 domain e'),
SEQ ID NO:55 (KLH1 domain f),
SEQ ID NO:56 (KLH1 domain g),
SEQ ID NO:57 (KLH2 domain b'),

Preliminary Amendment -51-
showing changes for
§ 371 Patent Application of PCT/EP00/02410
Markl, et al.
filed September 17, 2001

SEQ ID NO:58 (KLH2 domain c'),
SEQ ID NO:59 (KLH2 domain d'),
SEQ ID NO:60 (KLH2 domain e),
SEQ ID NO:61 (KLH2 domain f),
SEQ ID NO:62 (KLH2 domain g'),
SEQ ID NO:80 (HtH1 domain a" + signal peptide),
SEQ ID NO:81 (HtH1 domain b"),
SEQ ID NO:82 (HtH1 domain c"),
SEQ ID NO:83 (HtH1 domain d"),
SEQ ID NO:84 (HtH1 domain e"),
SEQ ID NO:85 (HtH1 domain f"),
SEQ ID NO:86 (HtH1 domain g"),
SEQ ID NO:87 (HtH1 domain h"),
SEQ ID NO:88 (partial HtH2 domain a"),
SEQ ID NO:89 (HtH2 domain b"),
SEQ ID NO:90 (HtH2 domain c"),
SEQ ID NO:91 (HtH2 domain d"),
SEQ ID NO:92 (HtH2 domain e"),
SEQ ID NO:93 (HtH2 domain f"),
SEQ ID NO:94 (HtH2 domain g"),
SEQ ID NO:95 (HtH2 domain h"),
SEQ ID NO:96 (partial KLH1 domain b"),
SEQ ID NO:97 (KLH1 domain c"),
SEQ ID NO:98 (KLH1 domain d"),
SEQ ID NO:99 (KLH1 domain e"),
SEQ ID NO:100 (KLH1 domain f"),
SEQ ID NO:101 (KLH1 domain g"),
SEQ ID NO:102 (KLH2 domain b"),
SEQ ID NO:103 (KLH2 domain c"),
SEQ ID NO:104 (KLH2 domain d"),
SEQ ID NO:105 (KLH2 domain e"),

Preliminary Amendment -52-
showing changes for
§ 371 Patent Application of PCT/EP00/02410
Markl, et al.
filed September 17, 2001

SEQ ID NO:106 (KLH2 domain f"),
SEQ ID NO:107 (KLH2 domain g"),
SEQ ID NO:108 (partial KLH2 domain h");

- (b) nucleic acid sequences which hybridize with the counter-strand of a nucleic acid sequence according to (a) and code for a polypeptide which has the immunological properties of at least one domain of a haemocyanin;
- (c) nucleic acid sequences which on the basis of the genetic code are degenerated to the DNA sequences defined under (a) and (b) and code for a polypeptide which has the immunological properties of at least one domain of a haemocyanin;
- (d) nucleic acid sequences which hybridize with one of the nucleic acid sequences described under (a) to (c) and the counter-strand of which codes for a polypeptide which has the immunological properties of at least one domain of a haemocyanin;
- (e) nucleic acid sequences which are at least 60% homologous to one of the nucleic acid sequences described under (a);
- (f) variants of the sequences described under (a) to (d), the variants containing additions, deletions, insertions or inversions with respect to the sequences described under (a) to (d) and coding for a polypeptide which has the immunological properties of at least one domain of haemocyanin;

Preliminary Amendment -53-
showing changes for
§ 371 Patent Application of PCT/EP00/02410
Markl, et al.
filed September 17, 2001

and

(g) combinations of several of the DNA sequences
described under (a) to (f) according to claim 42 and
B. ~~b)~~ detecting the specific binding.

44. Screening method according to claim
43, **characterized in that** the tumour to be detected
is a bladder carcinoma, epithelial carcinoma, ovarian
carcinoma, mammary carcinoma, bronchial carcinoma or
colorectal carcinoma.